Chronic Kidney Disease Trial, Recruiting NCT05282732 Sponsor: Fresenius Medical Care Deutschland GmbH Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Chronic Kidney Disease Trial, Recruiting

NCT05282732
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People with kidney failure who needed a blood-cleaning treatment (a machine that filters the blood outside the body) and received all of their treatments using the specific devices being studied, between January 2019 and December 2019 — records must be available in the order the treatments were given.
  • For patients who received acute (short-term) blood-cleaning treatment: records must show at least 3 out of 5 key measurements (daily urea, creatinine, potassium, fluid removed, and total fluid processed) for at least half of the documented treatment sessions.
  • For patients who received ongoing (long-term) blood-cleaning treatment: records must show the amount of fluid removed for every treatment session, plus at least one urea and one creatinine measurement per week.

Who may not be able to join:

  • People who were using a different filter or adsorber device at the same time for a separate type of therapy.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Martin Brauer, Dr. med., Jena University Hospital

Phone: +49 6172 608 2362

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Fresenius Medical Care Deutschland GmbH
Registry
ClinicalTrials.gov
Start date
7 October 2022
Est. completion
1 December 2025

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Daily values for urea, Unit: mg/dl or mmol/L; Daily values for creatinine, Unit: mg/dl or mmol/ or µmol/L; Daily values for potassium, Unit: mg/dl or mmol/ or µmol/L; Ultrafiltration volume (UF) and Effluent volume (per treatment); Values for urea and creatinine (measured according to the clinical practice of the site); Planned and delivered UF-volume (per treatment)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov